Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FVH1
- Development stage
- Phase 1
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
FVH1 is a DNA-based influenza vaccine designed to prevent infection and disease caused by the H1N1 influenza virus. It utilizes DNA plasmids containing genes that express viral antigens. The vaccine aims to induce serum antibodies, secretory IgA antibodies, and/or cell-mediated immunity (CMI). Electroporation via the CELLECTRA® device is used to enhance the delivery and expression of the H1N1 influenza virus genes in the vaccine.
Beyond the preview
Go deeper on FVH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FVH1.